Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jorge Cortes, Catherine Smith, Mark Litzow, Maria R. Baer, David Claxton, Harry P. Erba, Stan Gill, Stuart Goldberg, Joseph G. Jurcic, Richard A. Larson, Chaofeng Liu, Ellen Ritchie, Gary Schiller, Alexander I. Spira, Stephen A. Strickland, Raoul Tibes, Celalettin Ustun, Eunice S. WangRobert Stuart, Christoph Röllig, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark Levis

Research output: Contribution to journalArticlepeer-review

241 Scopus citations

Fingerprint

Dive into the research topics of 'Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences